1. Introduction {#s0005}
===============

Cutaneous localizations are frequently observed in healthcare-associated mucormycosis [@bib1]. In this setting, highly immunosuppressed patients such as those with hematological malignancy or transplantation are particularly at risk. In one study mucormycosis accounted for 2.3% of invasive fungal diseases in solid organ transplantation (SOT), with a mortality rate often approaching 50% [@bib2]. While the highest incidence rate was observed in liver transplant recipients, the estimated mucormycosis incidence in kidney transplant recipients ranged from 0.2% to 1.2% [@bib3]. In a large cohort of patients with invasive fungal diseases from 23 US transplant centers, cutaneous localization accounted for 13% of the 28 mucormycosis cases [@bib2]. The diagnosis of mucormycosis is often delayed in SOT [@bib4], but this is highly dependent on the infected site. However, even though skin localizations can be easily documented by skin biopsies, species identification remains difficult. In fact, in healthcare-associated mucormycosis, more than 30% of *Mucorales* species responsible for cutaneous involvement were unidentified [@bib1].

We report a subacute cutaneous mucormycosis in a kidney transplant recipient due to a very rare *Mucorale* species. It is possible that the infection was healthcare-associated. To our knowledge, this is the first reported case of *Mucor irregularis* infection in a solid organ transplant recipient. However, the management of mucormycosis in the SOT population differs from treatment in hematological patients, and the management of this specific *Mucorale* species is discussed.

2. Case {#s0010}
=======

A 69 year-old woman was admitted in March 2012 for subcutaneous nodular lesions on the back of the left hand and left elbow ([Fig. 1](#f0005){ref-type="fig"}). She had chronic renal failure secondary to a hemolytic uremic syndrome and had received two kidney transplants from cadaveric donors in 1987 and 1993. Her baseline creatinine serum level was 150 μmol/L. Her current immunosuppressive therapy was cyclosporine 50 mg b.i.d., azathioprine 50 mg/d and prednisolone 5 mg/d. One year earlier, she was diagnosed with an epidermoid carcinoma on the right leg, which was treated with radiation therapy. She also had a history of gout.

At the end of January 2012, she had corticosteroid infiltrations on the left radiocarpal and right metacarpus-phalangeal joints for a gout flare-up. Three weeks later, five-millimeter white subcutaneous nodules appeared, first on the left hand and then on the left elbow. The patient did not report previous injury to the left arm. She mentioned that she applied a moisturizer on both arms daily, but did not recall any contact with plants or animals.

On admission (day 0), the hand nodules had become ulcerated and purulent ([Fig. 1](#f0005){ref-type="fig"}A). Overall, the lesions were painless and the patient had no fever. No sign of arthritis or neurological abnormality were noted. Blood test results showed 6000 leukocytes/mm^3^, 800 lymphocytes/mm^3^, 200,000 platelets/mm^3^, hemoglobin 10.8 g/dL, C-reactive protein 6 mg/L, creatinine 195 μmol/L, glucose 16.4 mmol/L with HbA1c 8.1%, iron level 14 μmol/L, ferritin 774 μg/L, and LDH 548 UI/L. A skin biopsy was performed and histopathologic findings showed non-caseating eosinophilic necrosis, granulomatous histiocytic infiltrate, and multinucleate giant cells in the dermis and subcutis. Necrotic areas were surrounded by large, irregular, non-septate, wide-angle branching hyphae on periodic acid--Schiff and Grocott stainings ([Fig. 2](#f0010){ref-type="fig"}).

Cultures of biopsy specimens on Sabouraud chloramphenicol agar slants (BioRad Laboratories, Marnes-La-Coquette, France) incubated at 30 °C and 35 °C were positive (day+5) with profuse fluffy whitish colonies presenting a lemon-yellow reverse. The identification was performed by sequencing of the ITS1-5.8S-ITS2 region of the ribosomal DNA using the universal primers ITS1-ITS4 [@bib5]. The nucleotide sequence (deposited in Genbank under accession number KJ472786) had 100% identity over 451 bp for *M. irregularis* (formerly *Rhizomucor variabilis* var. *variabilis* [@bib6]), compared to the nucleotidic sequences of strains CMFCCC B 50 m and CBS 654.78 published under GenBank accession numbers JX976252 and JX976261 [@bib7]. Minimal inhibitory concentrations, measured by the *E*-test agar diffusion method (bioMérieux SA, Marcy l׳Etoile, France), were respectively 0.094, 12, 8 and \>32 µg/ml to amphotericin B (AmB), itraconazole, posaconazole and voriconazole, respectively.

To assess whether mucormycosis was localized to the skin or disseminated, we performed sinus, chest and abdominal computed tomography, as well as plain films of the left arm, and a cerebral magnetic resonance. All were normal. Cyclosporine and prednisolone were tapered and azathioprine was discontinued. Concurrent type 2 diabetes was balanced with oral medication. Liposomal amphotericin B (L-AmB) was immediately introduced at 3 mg/kg/day, and then increased at 5 mg/kg/day (day +9) due to progression of the lesions. During the course of therapy, the patient showed signs of L-AmB nephrotoxicity with serum creatinine increasing up to 380 μmol/L and respiratory distress due to pulmonary edema. Dialysis was performed twice. Given the severe nephrotoxicity to L-AmB, the drug was discontinued (day +21). The patient received a total of 1.1 g of L-AmB over 3 weeks. Extensive surgical debridement of the left hand and elbow was performed on day+13 ([Fig. 1](#f0005){ref-type="fig"}B). Progressive local improvement was noted in the following weeks. One month post-surgery (day+30), a skin graft was successfully performed. No mucormycosis relapse was noted 2 years after treatment discontinuation.

Suspecting a healthcare-associated infection, we attempted to look the presence of fungi in the corticosteroid vial, but it unfortunately could not be analyzed. However, no mucormycosis in patients receiving steroids infiltration was reported to the French National Institute for Health Surveillance (InVS) during the same period. In addition, the patient׳s skin moisturizer was also cultured on Sabouraud agar slants but no fungus was isolated.

3. Discussion {#s0015}
=============

In 1999, Voigt et al. reported that *R. variabilis* was misplaced in the *Rhizomucor* clade and would be better positioned within *Mucor* spp. [@bib8], and its name was changed to *M. irregularis*. This species was not reported in the recent French retrospective cohort of patients with mucormycosis [@bib4]. However, it has occasionally been responsible for cutaneous mucormycosis in China [@bib9; @bib10; @bib11], India [@bib12; @bib13], Japan [@bib14], USA [@bib15; @bib16] and Australia [@bib17]. The 12 documented cases are presented in [Table 1](#t0005){ref-type="table"}. Infections were all proven by skin or mucosal biopsies, with DNA sequencing of cultured isolates for cases published since 2009. This fungus exhibits a specific cutaneous tropism involving the uncovered skin. Chronic lesions lasting from several months to years have been described in immunocompetent patients [@bib9; @bib10; @bib11; @bib12; @bib13]. Although the incubation period is unknown, the infection seems to develop within few days in neutropenic patients [@bib15; @bib16], and rapidly in other immunocompromised hosts [@bib14]. Histopathological examination shows inflammatory granuloma in the dermis of patients with chronic infections [@bib10; @bib11; @bib12; @bib13], whereas it reveals dermis abscesses without granuloma in more acute forms [@bib15]. Although cutaneous mucormycosis due to other species of *Mucorales* often causes disseminated disease, *M. irregularis* infection can be localized, as in this case. Nevertheless, progressive tissue invasion and dissemination should be assessed, given the vascular tropism of these aggressive fungi, especially in immunocompromised hosts. Liposomal amphotericin B, ≥5 mg/kg/day, is the optimal treatment of these destructive mycoses and monotherapy is recommended as first line treatment [@bib18]. Posaconazole can be used as maintenance therapy, but some *Mucorales* species exhibit high MIC values to posaconazole. *M. irregularis* posaconazole MIC values are only rarely reported in the literature, but some authors reported MIC ranging from 0.25 to 2 µg/ml using the microdilution reference method [@bib12; @bib19]. Caspofungin alone has no activity against *Mucorales*. However, it already showed a good synergistic activity *in vitro* in combination with amphotericin B [@bib20]. *In vivo* positive effect of Caspofungin was seldom observed and always in combination with other antifungal drugs. In this case, liposomal amphotericin B had to be stopped because of nephrotoxicity and the other therapeutic option, posaconazole, could not be used due to high MIC values.

Surgery probably had a major impact on the favorable outcome in this case, since amphotericin B could not be prolonged more than one month and limited cumulative dose of 1.1 g was administered. Surgery has not been systematically performed for *M. irregularis* infections in the literature ([Table 1](#t0005){ref-type="table"}). The need for surgery seems to mainly depend on lesion extension and patient׳s overall condition. Hematological conditions, such as thrombocytopenia and neutropenia often increase risks associated with invasive procedures. Thus, neither of the two neutropenic cases had surgery to control the infection [@bib15; @bib16]. Extensive tissue debridement could be necessary to avoid progression, decrease fungal load, and allow for better diffusion of antifungal drugs through non-necrotic areas, especially in solid organ transplant recipients.

In our case, a healthcare-associated mucormycosis could not be ruled out. A recent literature review showed that 24% of the 169 patients with a healthcare-associated mucormycosis were solid organ recipients, 35% being kidney-transplanted [@bib1]. Diabetes was a cofactor in 57% of SOT cases, as in our case. Furthermore, corticosteroids injections have already been associated with localized cutaneous mucormycosis [@bib1]. Unfortunately we failed to demonstrate a link with steroids infiltrations or with the moisturizing cream used by the patient. However, the break in skin integrity due to the corticosteroid injection may have constituted a portal of entry for the *Mucorales* in the sub-cutaneous tissue. Inappropriate skin disinfection prior to the injection could also have contributed to the infection. Other potential environmental sources such as water, with which the breached skin could have been in contact with, were not investigated. Water is indeed a potential reservoir for fungi that infection control specialists and clinicians should not underestimate [@bib17]. This case also highlights the limitations associated with investigating an isolated case of suspected healthcare-associated invasive mucormycosis.
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![Cutaneous mucormycosis due to *Mucor irregularis* in a kidney-transplanted recipient. (A) Cutaneous lesions before liposomal amphotericin B treatment. (B) After large debridement on day+13 of liposomal amphotericin B.](gr1){#f0005}

![Histopathological examination of skin biopsy in a cutaneous mucormycosis due to *Mucor irregularis*. Within the dermis is a heavy mixed granulomatous and suppurative infiltrate extending to the subcutis. Fungi are located within histiocytic granulomas showing a large number of giant multinucleate cells. *Mucor irregularis* hyphae are very broad, non-septate and branch at 90°. They appear often twisted (Gomori-Grocott staining; ×400).](gr2){#f0010}

###### 

Proven cases of *Mucor irregularis* published in the literature.

  Country                          Age of cases       Gender              Localization   Comorbidities                                                         Disease duration   Treatment                                                        Duration   Outcome                                                                                   Ref.
  -------------------------------- ------------------ ------------------- -------------- --------------------------------------------------------------------- ------------------ ---------------------------------------------------------------- ---------- ----------------------------------------------------------------------------------------- ----------
  India                            [18]{.smallcaps}   [M]{.smallcaps}     Rhinofacial    None                                                                  12 years           Debridement; systemic fluconazole                                60 days    Improved                                                                                  [@bib12]
  Local fluconazole                90 days            Lost to follow up                                                                                                                                                                                                                                                                                 
                                   [50]{.smallcaps}   [M]{.smallcaps}     Arm            None                                                                  6 months           Fluconazole                                                      2 months   Lost to follow up                                                                         [@bib13]
                                                                                                                                                                                                                                                                                                                                                        
  Japan                            [78]{.smallcaps}   [M]{.smallcaps}     Legs           Type 2 diabetes, bladder cancer, rheumatoid arthritis, steroids       3 months           Debridement+L-AmB 5 mg/kg/day                                    12 weeks   Cured at EOT; no further follow-up                                                        [@bib14]
                                                                                                                                                                                                                                                                                                                                                        
  China                            [37]{.smallcaps}   [F]{.smallcaps}     Face, sinus    None                                                                  10 years           d-AmB total dose 1.5 g                                           3 months   Cured at 3-month follow up                                                                [@bib14]
  Itraconazole                     2 months                                                                                                                                                                                                                                                                                                             
                                   [37]{.smallcaps}   [F]{.smallcaps}     Hand           None                                                                  18 years           Ketoconazole                                                     ND         Recurrence                                                                                [@bib10]
                                   [54]{.smallcaps}   [F]{.smallcaps}     Face           None                                                                  16 years           Fluconazole                                                      ND         Recurrence                                                                                [@bib10]
                                   [33]{.smallcaps}   [M]{.smallcaps}     Arm            None                                                                  7 years            Itraconazole+terbinafine; d-AmB total dose 42.3 mg/kg            ND         Cured at EOT                                                                              [@bib10]
                                   [5]{.smallcaps}    [F]{.smallcaps}     Face           None                                                                  7 months           Itraconazole+terbinafine+bifonazole; d-AmB total dose 50 mg/kg   ND         Cured at EOT                                                                              [@bib10]
                                   [40]{.smallcaps}   [F]{.smallcaps}     Cheek          None                                                                  9 years            d-AmB total dose 3.2 mg/kg; itraconazole                         ND         Cured at EOT                                                                              [@bib10]
                                   [57]{.smallcaps}   [M]{.smallcaps}     Rhinofacial    None                                                                  3 years            Itraconazole                                                     3 months   Cured at EOT; no further follow-up                                                        [@bib9]
                                   [35]{.smallcaps}   [M]{.smallcaps}     Rhino-facial   None                                                                                     L-AmB+terbinafine                                                2 months   Cured at 1-year follow up                                                                 [@bib11]
                                                                                                                                                                                                                                                                                                                                                        
  USA                              [57]{.smallcaps}   [M]{.smallcaps}     Arms           Rheumatoid arthritis, acute myeloid leukemia, neutropenia, steroids   Few days           d-AmB total dose 770 mg                                          10 days    Cured at EOT; died from leukemia                                                          [@bib15]
  ABLC total dose 6.3 g            17 days                                                                                                                                                                                                                                                                                                              
  Posaconazole                     3 months                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                        
  USA                              [14]{.smallcaps}   [F]{.smallcaps}     Palate         Hematopoietic stem cell transplant recipient                          2 weeks            Posaconazole                                                     2 weeks    Improved after 4 weeks of treatment; died from *Hormographiella aspergillata* infection   [@bib16]
  Posaconazole                     6 weeks                                                                                                                                                                                                                                                                                                              
  +Caspofungin L-AmB+caspofungin   2 weeks                                                                                                                                                                                                                                                                                                              

d-AmB: amphotericin B deoxycholate; L-AmB:liposomal AmB; ABLC: amphotericin B lipid complex; EOT: end of therapy; ND: no data.
